Figure 3

Graphical representation (hive plots) of the disease–biomarker network in trials registered on ClinicalTrials.gov. (a) Hive plots for Ado-trastuzumab, Afatinib, Bosutinib, Crizotinib, Dabrafenib, and Dasatinib. (b) Hive plots for Lapatinib, Nilotinib, Panitumumab, Pertuzumab, Trametinib and Vemurafenib. Each hive plot represents a targeted therapy; within each plot, each trial is represented by a link between the biomarker used to restrict inclusion in the trial (vertical axis) and the disease studied (horizontal axis). The color of the link corresponds to the start year of the trial: green represents trials from 2002; yellow, studies from 2008; and red, trials from 2014; intermediate dates are represented by gradients between colors. Trials with a treat-all design are linked to the group “None” in the vertical axis. Multiple-disease trials are represented once for each studied disease, and multiple-drug trials are represented once for each studied drug. Biomarker–indication pairs for which genetic testing is recommended or required are in bold and indicated below the drug name, along with the proportion of corresponding trials.